Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial
Tags: cancer, immunomodulatory agent, multiple myeloma, Revlimid®, thalidomide derivative
BASi Method Number SAP.1729
Sign up and you’ll receive the latest updates that matter to you, delivered straight to your inbox.
